KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Current Leases (2019 - 2023)

Vir Biotechnology's Current Leases history spans 4 years, with the latest figure at $7.3 million for Q1 2023.

  • On a quarterly basis, Current Leases changed N/A to $7.3 million in Q1 2023 year-over-year; TTM through Mar 2023 was $7.3 million, a N/A change, with the full-year FY2022 number at $4.1 million, changed N/A from a year prior.
  • Current Leases hit $7.3 million in Q1 2023 for Vir Biotechnology, up from $4.1 million in the prior quarter.
  • Over the last five years, Current Leases for VIR hit a ceiling of $7.3 million in Q1 2023 and a floor of $200000.0 in Q1 2020.
  • Historically, Current Leases has averaged $1.8 million across 4 years, with a median of $300000.0 in 2020.
  • The widest YoY moves for Current Leases: up 26.58% in 2020, down 26.58% in 2020.
  • Tracing VIR's Current Leases over 4 years: stood at $237000.0 in 2019, then increased by 26.58% to $300000.0 in 2020, then surged by 1279.0% to $4.1 million in 2022, then soared by 75.68% to $7.3 million in 2023.
  • Business Quant data shows Current Leases for VIR at $7.3 million in Q1 2023, $4.1 million in Q4 2022, and $300000.0 in Q4 2020.